Patents by Inventor Shuwen He

Shuwen He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMPK ACTIVATORS
    Publication number: 20240101558
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Application
    Filed: November 1, 2023
    Publication date: March 28, 2024
    Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING
  • AMPK activators
    Patent number: 11851429
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 26, 2023
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He, Ann Weber, Nancy Thornberry, Lisa Krug, Paul Richards, Brett Lauring
  • GPR40 AGONISTS
    Publication number: 20230151037
    Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Application
    Filed: February 28, 2021
    Publication date: May 18, 2023
    Inventors: Iyassu SEBHAT, Shuwen HE, Simon MATHIEU
  • SSTR5 ANTAGONISTS
    Publication number: 20230113609
    Abstract: This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Application
    Filed: December 2, 2020
    Publication date: April 13, 2023
    Inventors: Iyassu SEBHAT, Shuwen HE, Christopher MOYES, Simon MATHIEU, Michael LUZUNG
  • GPR119 AGONISTS
    Publication number: 20230061736
    Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Application
    Filed: July 28, 2022
    Publication date: March 2, 2023
    Inventors: Iyassu SEBHAT, Shuwen HE, Christopher MOYES
  • SSTR5 ANTAGONISTS
    Publication number: 20230050965
    Abstract: This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Application
    Filed: December 2, 2020
    Publication date: February 16, 2023
    Inventors: Iyassu SEBHAT, Shuwen HE
  • SSTR5 ANTAGONISTS
    Publication number: 20230041621
    Abstract: This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Application
    Filed: December 2, 2020
    Publication date: February 9, 2023
    Inventors: Iyassu SEBHAT, Shuwen HE
  • NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20230008022
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: November 25, 2019
    Publication date: January 12, 2023
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, Andreas Verras, Li Xiao, Feng Ye, Wensheng Yu, Rui Zhang
  • GPR119 agonists
    Patent number: 11512065
    Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: November 29, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He, Christopher Moyes
  • AMPK ACTIVATORS
    Publication number: 20220340599
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.
    Type: Application
    Filed: June 22, 2022
    Publication date: October 27, 2022
    Inventors: Iyassu SEBHAT, Shuwen HE
  • [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 11478461
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 25, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Liangqin Guo, Hongjun Zhang, Ping Chen, Dane Clausen, Xavier Fradera, Yongxin Han, Shuwen He, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Li Xiao, Feng Ye
  • GPR40 AGONISTS
    Publication number: 20220289772
    Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Application
    Filed: May 16, 2022
    Publication date: September 15, 2022
    Inventors: Iyassu SEBHAT, Shuwen HE
  • AMPK activators
    Patent number: 11407768
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: August 9, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He
  • GPR40 AGONISTS
    Publication number: 20220226298
    Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 21, 2022
    Inventors: Iyassu SEBHAT, Shuwen HE
  • AMPK ACTIVATORS
    Publication number: 20220227754
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Application
    Filed: January 26, 2022
    Publication date: July 21, 2022
    Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING
  • Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 11352320
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: June 7, 2022
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Shuwen He, Dane Clausen, Liangqin Guo, Yongxin Han, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Dong Xiao, Li Xiao, Feng Ye, Hongjun Zhang
  • GPR119 AGONISTS
    Publication number: 20220153719
    Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 19, 2022
    Inventors: Iyassu SEBHAT, Shuwen HE, Christopher MOYES
  • AMPK activators
    Patent number: 11279702
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: March 22, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He
  • [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 11267786
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: March 8, 2022
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Shuwen He, Yongxin Han, Alexander Pasternak
  • AMPK ACTIVATORS
    Publication number: 20220033401
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING